截至2025年9月5日收盘，麦澜德（688273）报收于39.71元，较上周的41.96元下跌5.36%。本周，麦澜 德9月1日盘中最高价报42.25元。9月4日盘中最低价报38.03元。麦澜德当前最新总市值39.71亿元，在医 疗器械板块市值排名96/126，在两市A股市值排名3850/5152。 本周关注点 业绩披露要点 2025年上半年，公司实现营收2.41亿元，同比增长5.62%，增长主要来自生殖康复和抗衰产品线；归母 净利润为6,392.01万元，同比下降11.96%，主因系处置子公司的不良资产。 机构调研要点 情感交互产品依托国家重点研发计划项目，预计2027年结题，目前处于中期阶段，已形成原理样机，计 划年内开展临床预实验。技术原理基于多模态生理信号、动作、表情、语音等信息识别，通过算法融合 实现阿尔茨海默病早期风险识别，并结合认知干预延缓病情发展，过程中实时进行情绪识别与调控。 多中心临床研究有助于增强盆底磁刺激仪在泌尿外科领域的医学证据，提升产品价值。通过头部医院积 累病例和建设标杆中心，为后续医院准入提供考察点，加快设备进院。 海外业务以盆底产品为主，重点市场为东南亚地区。公司通过参展和学 ...

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and the orderly conduct of the meeting [1][2] - The meeting will include voting on key proposals, including the reappointment of the accounting firm and amendments to the company's articles of association [5][6] Meeting Procedures - All attendees must comply with legal obligations to maintain the rights of shareholders and the order of the meeting [1] - Only authorized personnel, including shareholders, directors, supervisors, and legal representatives, are allowed to attend the meeting [2] - Shareholders must sign in 30 minutes before the meeting and present necessary identification documents [3] - Voting will be conducted both on-site and online, with each share carrying one vote [5][6] Agenda Items - Proposal One: Reappointment of Zhongxinghua Accounting Firm as the auditor for the fiscal year 2025, which has been approved by the board's audit committee [6] - Proposal Two: Cancellation of the supervisory board and amendments to the company's articles of association to enhance corporate governance [7][8]

2025 年 9 月 南京麦澜德医疗科技股份有限公司 2025 年第二次临时股东大会会议资料 目 录 | 年第二次临时股东大会会议须知 3 2025 | | --- | | 2025 年第二次临时股东大会会议议程 5 | | 议案一：关于续聘会计师事务所的议案 7 | | 议案二：关于取消监事会、修订《公司章程》并办理工商变更登记的议案 8 | | 议案三：关于修订及新增公司部分治理制度的议案 41 | 南京麦澜德医疗科技股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司 2025 年第二次临时股东大会会议资料 南京麦澜德医疗科技股份有限公司 2025 年第二次临时股东大会会议资料 南京麦澜德医疗科技股份有限公司 2025 年第二次临时股东大会会议须知 为维护全体股东的合法权益，确保南京麦澜德医疗科技股份有限公司（以下 简称"公司"）股东大会顺利进行，根据《中华人民共和国证券法》《中华人民共和 国公司法》等法律法规及《南京麦澜德医疗科技股份有限公司章程》和公司《股 东大会议事规则》的相关规定，制定以下会议须知，请出席股东大会的全体人员 ...

3）麦澜德 （呈瑞投资参与公司特定对象调研） 调研纪要：2025年上半年，公司实现营收2.41亿元，同比增长5.62%；归母净利润6,392.01万元，同比下 降11.96%，主因处置子公司不良资产。生殖康复和抗衰业务收入7,983.87万元，同比增长42.45%。毛利 率下降因新品推广策略调整及大客户订单增加。公司聚焦非侵入式脑机接口，已在多模态生理信号采集 等领域形成技术积累。情感交互产品已形成原理样机，计划年内开展临床预实验。多中心临床研究助力 产品进院。海外业务主推东南亚市场。康美中心今年目标在江浙打造样板。公司坚持"一端更严肃，一 端更消费"战略，推动双轮驱动。 机构简介： 上海呈瑞管理有限公司2010年5月成立于上海，注册资金1100万。公司于2014年4月登记为私募投资基金 管理人，2015年3月成为中国证券投资基金业协会观察会员。公司主营二级市场，涵盖大类资产配置， 主要策略包括宏观对冲策略，高频Alpha策略，CTA策略，策略平台均属自行开发运行，多年以来稳健 发展，公司不断受到市场广泛认可，客户群体不断多元化，涵盖银行资管、私行、券商、保险、信托、 各类fof机构和央企等客户青睐。目前公司 ...

Core Viewpoint - The company, 麦澜德 (688273), reported a revenue increase of 5.62% year-on-year for the first half of 2025, but a decline in net profit by 11.96% due to the disposal of a subsidiary's bad assets [2][11]. Financial Performance - The company achieved a revenue of 241 million yuan in the first half of 2025, with a net profit of 63.92 million yuan [2][11]. - The gross profit margin was reported at 70.9%, with a decline attributed to adjustments in sales strategies during the new product promotion phase and an increase in orders from major clients [3][11]. - In Q2 2025, the company recorded a revenue of 123 million yuan, a decrease of 0.89% year-on-year, and a net profit of 24.06 million yuan, down 33.76% year-on-year [11]. Business Segments - The reproductive rehabilitation and anti-aging product lines generated revenue of 79.84 million yuan, reflecting a growth of 42.45% year-on-year [4]. - The company focuses on a dual strategy of serious medical and consumer medical services, leveraging clinical data to support consumer medical offerings [11]. Technological Development - The company is developing non-invasive brain-machine interface technologies, with ongoing projects in upper limb and hand movement robotics, non-invasive neural regulation, and multi-modal physiological signal collection [5]. - A key project, "Multi-modal Emotional Interactive Diagnostic Equipment Development," is expected to conclude in 2027, aiming to identify early risks of diseases like Alzheimer's through multi-modal signal recognition [6]. Market Expansion - The company is actively promoting its overseas business, primarily focusing on pelvic floor products in Southeast Asia, despite facing challenges [8]. - The 康美 center initiative aims to create a new model of health management centers in collaboration with hospitals, with plans to establish pilot centers in regions like Jiangsu and Zhejiang [9]. Clinical Research - Ongoing multi-center clinical studies are enhancing the medical evidence for the pelvic floor magnetic stimulation device in urology, facilitating faster hospital access for the product [7].

8月28日，麦澜德跌1.51%，成交额1.51亿元。两融数据显示，当日麦澜德获融资买入额1469.10万元， 融资偿还2295.45万元，融资净买入-826.35万元。截至8月28日，麦澜德融资融券余额合计1.59亿元。 分红方面，麦澜德A股上市后累计派现2.68亿元。 机构持仓方面，截止2025年6月30日，麦澜德十大流通股东中，华夏稳增混合（519029）位居第三大流 通股东，持股125.21万股，相比上期增加14.17万股。中信建投轮换混合A（003822）位居第五大流通股 东，持股65.62万股，为新进股东。中信建投甄选混合A（008347）位居第七大流通股东，持股56.33万 股，为新进股东。汇添富成长焦点混合（519068）位居第十大流通股东，持股36.38万股，相比上期减 少29.94万股。汇添富医药保健混合（470006）、国泰医药健康股票A（009805）、融通健康产业灵活配 置混合A/B（000727）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，南京麦澜德医疗科技股份有限公司位于江苏省南京市雨花台区凤展路32号A2栋，成立日期 2013年1月16日，上市日期2022年8月11日， ...

据证券之星公开数据整理，近期麦澜德(688273)发布2025年中报。根据财报显示，麦澜德增收不增利。 截至本报告期末，公司营业总收入2.41亿元，同比上升5.62%，归母净利润6392.01万元，同比下降 11.96%。按单季度数据看，第二季度营业总收入1.23亿元，同比下降0.89%，第二季度归母净利润 2406.04万元，同比下降33.76%。 本次财报公布的各项数据指标表现一般。其中，毛利率70.9%，同比减2.87%，净利率26.7%，同比减 19.66%，销售费用、管理费用、财务费用总计7348.24万元，三费占营收比30.46%，同比增9.33%，每股 净资产13.36元，同比减0.71%，每股经营性现金流0.29元，同比减36.68%，每股收益0.65元，同比减 10.9% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 2.28ZZ | 2.41亿 | 5.62% | | 归母净利润(元) | 7260.67万 | 6392.01万 | -11.96% | | 扣非净利润(元) | 6605.9 ...

Financial Performance - The company reported a total revenue of 241 million yuan for the first half of 2025, an increase of 5.62% year-on-year [1] - The net profit attributable to shareholders was 63.92 million yuan, a decrease of 11.96% compared to the previous year [1] - The gross margin was 70.9%, down 2.87% year-on-year, while the net margin decreased by 19.66% to 26.7% [1] - Total expenses (selling, administrative, and financial) amounted to 73.48 million yuan, accounting for 30.46% of revenue, an increase of 9.33% year-on-year [1] Key Financial Ratios - The company's return on invested capital (ROIC) was 7.34% last year, indicating average capital returns [3] - The historical median ROIC since the company went public is 37.57%, with the lowest ROIC recorded in 2023 at 5.65% [3] - The company has a healthy cash asset position, indicating good debt repayment capability [3] Market Position and Fund Holdings - The company is primarily driven by marketing efforts, which require further analysis to understand the underlying dynamics [3] - Notably, a prominent fund manager, Zhuan Jiangwei from CITIC Jiantou Fund, has increased holdings in the company, ranking among the top fifty fund managers in 2024 [3] - The largest fund holding the company is Huaxia Stable Growth Mixed Fund, with a scale of 1.146 billion yuan and a recent net value of 3.246, reflecting a 92.71% increase over the past year [4] Business Insights - The company's pelvic floor rehabilitation business is primarily composed of an in-hospital market, which accounts for over 85% of its customer base [5] - The out-of-hospital market has seen a decline in business share due to fertility rates, but the overall business volume has stabilized in recent years [5]

Group 1 - Aofei Data achieved a net profit of 87.89 million yuan in the first half of 2025, a year-on-year increase of 16.09% [1] - Aofei Data's revenue for the same period was 1.148 billion yuan, up 8.20% year-on-year [1] - The company specializes in IDC services, internet business, system integration, and distributed photovoltaic energy-saving services [1] Group 2 - Meilan De reported a net profit of 63.92 million yuan, a year-on-year decrease of 11.96% [1] - The company's revenue was 241 million yuan, reflecting a growth of 5.62% year-on-year [1] - Meilan De focuses on the research, production, sales, and service of medical devices related to pelvic and obstetric rehabilitation [1] Group 3 - Jiuan Medical posted a net profit of 920 million yuan, a significant year-on-year increase of 52.91% [1] - The company's revenue decreased by 43.35% to 765 million yuan [1] - Jiuan Medical specializes in the research, production, and sales of home medical devices [2] Group 4 - Hanbang Technology's net profit fell by 26.24% to 27.80 million yuan [2] - The company achieved a revenue of 349 million yuan, a growth of 5.99% year-on-year [2] - Hanbang Technology provides professional separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [2] Group 5 - Jinjing Environment reported a net profit of 78.69 million yuan, a year-on-year increase of 13.73% [2] - The company's revenue was 782 million yuan, reflecting a growth of 1.70% [2] - Jinjing Environment focuses on investment operation management services and equipment manufacturing in the environmental sanitation sector [2] Group 6 - Tianbao Infrastructure achieved a net profit of 118 million yuan, a remarkable year-on-year increase of 2106.58% [3] - The company's revenue decreased by 8.31% to 486 million yuan [3] - Tianbao Infrastructure is involved in real estate development, property leasing, and management [4] Group 7 - Weihuaxin Materials reported a net profit of 83.15 million yuan, a year-on-year decrease of 52.91% [5] - The company's revenue was 437 million yuan, down 30.71% year-on-year [5] - Weihuaxin Materials specializes in the research and production of chlorotoluene and trifluoromethylbenzene products [5] Group 8 - Tianchen Medical posted a net profit of 48.21 million yuan, a year-on-year increase of 67.10% [6] - The company's revenue was 156 million yuan, reflecting a growth of 17.66% [6] - Tianchen Medical focuses on the research, innovation, and production of high-end surgical staplers [6] Group 9 - Greenland Holdings reported a net loss of 3.506 billion yuan in the first half of 2025 [8] - The company's revenue was 9.45 billion yuan, down 18.06% year-on-year [8] - Greenland Holdings is involved in various financial services including securities, futures, and trust [8] Group 10 - Wukuang Capital's net profit decreased by 41.47% to 525 million yuan [9] - The company achieved a total revenue of 623 million yuan, a significant increase of 144.86% [9] - Wukuang Capital operates in the financial sector, providing services such as securities and leasing [9] Group 11 - Yutong Technology reported a net profit of 554 million yuan, a year-on-year increase of 11.42% [10] - The company's revenue was 7.876 billion yuan, reflecting a growth of 7.10% [10] - Yutong Technology specializes in the research, design, production, and sales of paper packaging products [10] Group 12 - Wewei Co. posted a net profit of 120 million yuan, a year-on-year decrease of 20.14% [11] - The company's revenue was 1.521 billion yuan, down 12.76% year-on-year [11] - Wewei Co. focuses on the production and sales of various food and beverage products [11] Group 13 - Tongfang Co. reported a net loss of 256 million yuan in the first half of 2025 [12] - The company's revenue was 5.667 billion yuan, down 10.09% year-on-year [12] - Tongfang Co. is engaged in the development of smart technology and nuclear technology applications [12] Group 14 - Liugang Co. achieved a net profit of 368 million yuan, a year-on-year increase of 579.54% [13] - The company's revenue was 34.675 billion yuan, down 8.32% [13] - Liugang Co. specializes in coke, sintering, iron, steel smelting, and steel processing [13] Group 15 - China National Petroleum Corporation reported a net profit of 83.993 billion yuan, with a proposed dividend of 0.22 yuan per share [14] - The company's revenue was 1.45 trillion yuan, down 6.7% year-on-year [14] - The company is involved in oil and gas exploration, production, refining, and sales [14] Group 16 - Fangda Carbon's net profit decreased by 68.31% to 54.53 million yuan [15] - The company's revenue was 1.690 billion yuan, down 28.13% year-on-year [15] - Fangda Carbon specializes in the research, production, and sales of graphite and carbon materials [15] Group 17 - Xinmai Medical reported a net profit of 31.5 million yuan, a year-on-year decrease of 22.03% [18] - The company's revenue was 714 million yuan, down 9.24% year-on-year [18] - Xinmai Medical focuses on the research, production, and sales of vascular intervention medical devices [18] Group 18 - Hengbao Co. posted a net profit of 35.35 million yuan, a year-on-year decrease of 44.41% [19] - The company's revenue was 430 million yuan, down 8.64% year-on-year [19] - Hengbao Co. specializes in high-end intelligent products and digital security solutions [19] Group 19 - Zhongji Xuchuang reported a net profit of 3.995 billion yuan, a year-on-year increase of 69.40% [20] - The company's revenue was 14.789 billion yuan, reflecting a growth of 36.95% [20] - Zhongji Xuchuang specializes in high-end optical communication modules and devices [20] Group 20 - Guangxian Media achieved a net profit of 2.229 billion yuan, a year-on-year increase of 371.55% [21] - The company's revenue was 3.242 billion yuan, up 143.00% year-on-year [21] - Guangxian Media focuses on investment, production, and distribution of film projects [21] Group 21 - Huarun Pharmaceutical reported a net profit of 37.33 million yuan, a year-on-year decrease of 49.01% [23] - The company's revenue was 624 million yuan, down 19.13% year-on-year [23] - Huarun Pharmaceutical specializes in pharmaceuticals, medical devices, and health products [23] Group 22 - Huawai Technology posted a net profit of 12.7 million yuan, a year-on-year increase of 56.18% [24] - The company's revenue was 937 million yuan, reflecting a growth of 32.62% [24] - Huawai Technology focuses on the research, production, and sales of high-end elastic components [24]

2024年1至12月份，麦澜德的营业收入构成为：医疗器械占比69.32%，其他占比29.23%，其他业务占比 1.45%。 截至发稿，麦澜德市值为46亿元。 每经AI快讯，麦澜德（SH 688273，收盘价：45.55元）8月26日晚间发布公告称，公司第二届第十五次 董事会会议于2025年8月25日以现场及通讯方式召开。会议审议了《关于 <公司2025年半年度报告> 及 摘要的议案》等文件。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 （记者 王可然） ...